Sera Prognostics (SERA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Jun, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with proxy materials distributed starting April 24, 2026.
Supplement issued to update shareholders on a change in board nominees.
Voting matters and shareholder proposals
Jeffrey T. Elliott, previously nominated for re-election, has resigned effective June 4, 2026, and is no longer a nominee.
Board size reduced to seven directors; no substitute nominee will be named.
All other nominees remain up for re-election; proxy cards remain valid, but votes for Elliott will be disregarded.
No changes to other agenda items in the proxy statement.
Board of directors and corporate governance
Elliott’s resignation was not due to any disagreement regarding company operations, policies, or practices.
Board composition adjusted to reflect the reduced number of directors.
Latest events from Sera Prognostics
- Strong trial results drive rapid state and payer engagement for preterm birth screening.SERA
TD Cowen 46th Annual Health Care Conference18 May 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation8 May 2026 - Net loss of $8.4M and $14,000 revenue, with cash runway extended through 2029.SERA
Q1 20267 May 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving neonatal outcomes and reducing costs.SERA
Corporate presentation6 May 2026 - Director elections, auditor ratification, and ESG priorities highlight this year's proxy.SERA
Proxy filing24 Apr 2026 - Vote on director elections and auditor ratification at the June 2026 virtual annual meeting.SERA
Proxy filing24 Apr 2026 - PRIME study validated efficacy, commercial expansion advanced, and cash runway secured.SERA
Q4 202518 Mar 2026 - PreTRM enables early, validated prediction of preterm birth, reducing NICU admissions and costs.SERA
Corporate presentation18 Mar 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation2 Mar 2026